OpRegen for macular degeneration

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Geographic Atrophy

Why this status

  1. 7 Nov 2014: Trial registered, NCT02286089
  2. 1 Apr 2015: Trial started, NCT02286089

The trials

NCT02286089: Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

State
Under way
Phase
Phase 1 and Phase 2
People
24 taking part
Started
1 Apr 2015
Primary completion
31 Dec 2021
Arms
OpRegen
Results
Posted on the registry
  1. 7 Nov 2014: Trial registered
  2. 1 Apr 2015: Trial started
  3. 6 Mar 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.